Last updated: September 24, 2026
The 40/5/25 mg fixed-dose combination combines an angiotensin II receptor blocker, a calcium-channel blocker, and a thiazide diuretic. The reference product is Tribenzor, marketed by Daiichi Sankyo for hypertension. The principal commercial opportunity is a bioequivalent generic tablet with low manufacturing cost, robust dissolution performance, acceptable tablet size, and reliable stability across three chemically different active ingredients.
The strongest excipient strategy is a conventional immediate-release, film-coated tablet using a moisture-controlled diluent and disintegrant system, supported by tight control of particle size, blend uniformity, compression force, and dissolution. Differentiated products could target low-cost supply, smaller tablets, dose flexibility, modified packaging, or a lower-risk excipient profile.
What is olmesartan medoxomil, amlodipine and hydrochlorothiazide 40/5/25 mg?
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg contains:
| Component |
Amount per tablet |
Pharmacologic role |
| Olmesartan medoxomil |
40 mg |
Angiotensin II receptor blocker |
| Amlodipine, supplied as amlodipine besylate |
Equivalent to 5 mg amlodipine |
Calcium-channel blocker |
| Hydrochlorothiazide |
25 mg |
Thiazide diuretic |
Tribenzor was approved by the U.S. Food and Drug Administration in 2010 for blood-pressure reduction in patients requiring combination therapy. The label permits use as replacement therapy or as add-on therapy when blood pressure is not adequately controlled with two agents.[1]
The combination addresses complementary mechanisms:
- Olmesartan reduces angiotensin II-mediated vasoconstriction and aldosterone activity.
- Amlodipine produces arterial vasodilation.
- Hydrochlorothiazide increases sodium and water excretion.
The product is an immediate-release oral tablet. Its commercial value comes from reducing pill burden for patients who otherwise require three separate antihypertensive medicines.
What excipients are used in the reference formulation?
The Tribenzor label identifies a conventional tablet formulation containing excipients such as microcrystalline cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, talc, titanium dioxide, and colorants.[1]
The reference composition is commercially relevant for two reasons. First, it indicates that the product does not require a complex delivery technology. Second, it provides a practical starting point for a generic formulation, although an ANDA applicant does not need to copy the reference excipient system exactly.
The generic product must demonstrate pharmaceutical equivalence and bioequivalence. Excipients can differ when they do not change safety, performance, dissolution, or bioavailability in a clinically meaningful manner.[2]
How should the excipient strategy address the three active ingredients?
The formulation must reconcile different dose levels, physicochemical properties, and stability risks.
Olmesartan medoxomil
Olmesartan medoxomil is a prodrug that is hydrolyzed during absorption to olmesartan. It has limited aqueous solubility and can create dissolution risk if the drug substance has large particles, poor wetting, or excessive hydrophobicity.
Useful excipient functions include:
- A water-compatible diluent such as microcrystalline cellulose or lactose.
- A rapid disintegrant such as low-substituted hydroxypropyl cellulose, crospovidone, or croscarmellose sodium.
- A wetting aid where needed.
- Controlled lubricant concentration to avoid hydrophobic overcoating.
- Particle-size engineering or micronization of the active pharmaceutical ingredient.
The development target should be rapid and reproducible dissolution across the physiological pH range relevant to immediate-release testing.
Amlodipine besylate
Amlodipine besylate is used to improve handling and solid-state stability. Amlodipine formulations require attention to light exposure, oxidative stress, and blend uniformity because the dose of amlodipine is relatively small compared with the total tablet mass.
Recommended controls include:
- Low-shear blending sufficient to prevent segregation.
- A validated assay and content-uniformity method.
- Protection from excessive light during manufacturing and storage.
- Evaluation of antioxidants only when justified by compatibility data.
- Avoidance of reactive impurities in excipients, especially aldehydes and peroxides.
Amlodipine represents the principal content-uniformity challenge in the 40/5/25 mg tablet because the active dose is only 5 mg.
Hydrochlorothiazide
Hydrochlorothiazide is present at a larger dose than amlodipine but remains sensitive to formulation variables that affect wetting, particle dispersion, and dissolution.
The formulation should control:
- Active-particle size and morphology.
- Blend segregation.
- Exposure to humidity.
- Lubrication time.
- Compression force and tablet porosity.
Hydrochlorothiazide can be incorporated into a conventional direct-compression or dry-granulation platform if flow and compressibility are adequate. Wet granulation may improve uniformity and manufacturability but introduces water exposure and a more complex process.
Which excipient platforms are commercially viable?
Direct compression
Direct compression offers the lowest process cost and the shortest manufacturing route. It is attractive when all three active ingredients have acceptable flow, compressibility, and particle-size control.
A candidate platform could use:
| Function |
Candidate excipient classes |
| Primary diluent |
Microcrystalline cellulose, lactose, mannitol |
| Secondary diluent |
Dibasic calcium phosphate or spray-dried lactose |
| Disintegrant |
Crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose |
| Binder |
Copovidone or hydroxypropyl cellulose |
| Glidant |
Colloidal silicon dioxide |
| Lubricant |
Magnesium stearate or sodium stearyl fumarate |
| Film coating |
Hypromellose-based aqueous coating |
Direct compression is commercially strongest when the product can achieve acceptable hardness without slowing dissolution.
Dry granulation
Roller compaction can improve flow, reduce segregation, and support continuous or high-throughput production. It avoids the water exposure associated with wet granulation.
The main risk is overcompaction. Excessive ribbon density can produce tablets with slow disintegration and incomplete dissolution. The process requires control of specific compaction force, milling screen size, granule-size distribution, and lubricant mixing.
Wet granulation
Wet granulation can improve content uniformity and compressibility, particularly when the active ingredients have different densities or poor flow. It is less attractive where hydrolysis, moisture sensitivity, or high process cost creates a disadvantage.
Aqueous granulation should be supported by degradation studies for olmesartan medoxomil and amlodipine. A nonaqueous process can reduce water exposure but increases solvent-handling, residual-solvent, and environmental burdens.
What formulation patents protect the product?
The commercial protection for this product historically rested on a combination of active-ingredient patents, fixed-dose combination claims, formulation claims, and regulatory exclusivity. The original Tribenzor approval was granted in 2010, and the product is now in the mature generic stage.[1,3]
The relevant patent categories are:
- Olmesartan medoxomil composition patents. These protected the active compound and related pharmaceutical compositions.
- Amlodipine and hydrochlorothiazide patents. The underlying active ingredients are long-established and generally outside primary patent protection.
- Combination patents. These may claim the simultaneous use of olmesartan medoxomil, amlodipine, and hydrochlorothiazide or particular dose ranges.
- Formulation patents. Claims may cover excipient combinations, dissolution behavior, stability, coating systems, or manufacturing processes.
- Method-of-use patents. Claims may cover treatment of hypertension or patient populations requiring multi-agent therapy.
- Process patents. These may concern preparation of olmesartan medoxomil, solid forms, impurity control, or tablet manufacture.
A current freedom-to-operate review should distinguish expired patents from any unexpired formulation, process, or method-of-use claims. The FDA Orange Book remains the primary source for patents listed against the reference drug, while USPTO and international patent databases are required for a complete geographic review.[3,4]
What is the Orange Book and FDA regulatory status?
Tribenzor is an FDA-approved new drug application product. The reference application is NDA 200958.[1,3]
The regulatory pathway for a generic 40/5/25 mg product is generally an ANDA based on:
- Pharmaceutical equivalence.
- Comparative dissolution.
- In vivo bioequivalence where required.
- Manufacturing controls.
- Stability data.
- Labeling that is consistent with the reference product, subject to permitted differences.
The fixed-dose combination does not create a biosimilar issue. Biosimilar regulation applies to biological products, while this product contains small-molecule active ingredients. The relevant competitive pathway is generic substitution, not an abbreviated biologics license application.
The Orange Book should be reviewed for:
- Active listed patents.
- Expired patents.
- Pediatric exclusivity.
- Any remaining regulatory exclusivity.
- Therapeutic-equivalence codes for approved generic products.
For a mature product of this age, commercial risk is generally driven more by formulation execution, manufacturing cost, supply reliability, and price erosion than by new-drug exclusivity.
When does the product lose exclusivity?
The principal product-level regulatory exclusivity expired years after the 2010 approval period. The active ingredients also have long-established generic markets. Commercial entry therefore depends primarily on patent certification and the status of listed claims rather than on new chemical entity exclusivity.
Potential ANDA certifications include:
- Paragraph I: no patent information is listed.
- Paragraph II: listed patents have expired.
- Paragraph III: the applicant will wait for patent expiration.
- Paragraph IV: the applicant asserts that listed patents are invalid, unenforceable, or not infringed.
A Paragraph IV filing can create litigation risk under the Hatch-Waxman framework. The filing of a patent-infringement action within the statutory period can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court rulings.[5]
What generic entry risks exist?
The most important generic-entry risks are technical and commercial.
Technical risks
- Failure to match dissolution across relevant pH conditions.
- Amlodipine content-uniformity failures.
- Degradation caused by moisture, light, or reactive excipient impurities.
- Excessive magnesium stearate or overmixing that slows dissolution.
- Segregation caused by different active-ingredient particle sizes and densities.
- Tablet defects caused by high drug loading or poor compaction.
Regulatory risks
- Unacceptable differences from the reference formulation.
- Inadequate justification for excipient changes.
- Failure to establish bioequivalence.
- Incomplete extractables, leachables, or packaging controls.
- Patent litigation after a Paragraph IV certification.
Commercial risks
- Rapid price erosion after multiple ANDA approvals.
- Low reimbursement for a three-drug combination.
- Competition from separate generic tablets.
- Limited pharmacy stocking if demand is fragmented by dose.
- Wholesaler concentration and rebate pressure.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can pursue several opportunities around the 40/5/25 mg product.
High-performance immediate-release platforms
A prequalified platform using microcrystalline cellulose, a superdisintegrant, a low-peroxide binder, and a robust film-coating system can reduce development time for generic manufacturers.
Low-moisture and low-peroxide systems
Excipient grades with controlled moisture, peroxide, aldehyde, and metal-ion content can reduce degradation risk. This positioning is particularly relevant for products containing amlodipine and olmesartan medoxomil.
Direct-compression solutions
Co-processed excipients can improve flow, compactibility, and disintegration. The commercial value is strongest where they eliminate wet granulation or reduce roller-compaction complexity.
Smaller-tablet technologies
A smaller tablet can improve swallowing and reduce packaging volume. High-functionality excipients, optimized particle size, and higher tablet tensile strength can support size reduction without sacrificing dissolution.
Flexible manufacturing
A platform that supports multiple dose strengths, such as 20/5/12.5 mg, 40/5/12.5 mg, 40/10/25 mg, and 40/10/12.5 mg, can reduce formulation-development and tooling costs across the product family.
How does the product compare with competing antihypertensive combinations?
| Product type |
Main commercial advantage |
Main limitation |
| Olmesartan/amlodipine/HCTZ |
Three mechanisms in one tablet |
Greater formulation and pricing complexity |
| Olmesartan/amlodipine |
Two-drug control with lower pill burden |
May require a separate diuretic |
| Amlodipine/valsartan/HCTZ |
Established three-drug category |
Competes directly for the same patients |
| Separate generic tablets |
Lowest unit cost and flexible titration |
Higher pill burden |
| Single-agent therapy |
Simple prescribing and low cost |
Often inadequate for resistant hypertension |
The product is most competitive in patients who require all three agents at fixed doses. It is less competitive when prescribers need frequent dose titration or when patients tolerate only two components.
What patent litigation and settlement issues matter?
Litigation risk should be assessed at the patent-family level rather than by the product name alone. Relevant issues include:
- Whether a listed patent claims the exact 40/5/25 mg combination.
- Whether the claim requires a specific excipient or dissolution profile.
- Whether a method-of-use claim is carved out through labeling.
- Whether a settlement includes a licensed entry date.
- Whether the settlement restricts manufacturing, supply, or authorized-generic rights.
A settlement agreement can materially change the launch date even when a patent appears vulnerable. Commercial diligence should therefore review court dockets, FDA patent listings, ANDA filing dates, and settlement terms together.[3,5]
What is the revenue opportunity?
Revenue depends on market share, net price, payer mix, and the number of competing ANDAs. The branded product benefits from convenience, but the category is exposed to generic substitution and low-cost alternatives.
The strongest commercial models are:
- First-wave generic launch, supported by a Paragraph IV strategy where legally viable.
- Reliable secondary-source supply for large generic manufacturers.
- Authorized-generic or licensing arrangements with the reference-product holder.
- Regional commercialization in markets where three-drug fixed-dose combinations remain underpenetrated.
- Formulation-platform licensing to companies seeking rapid development of multiple antihypertensive combinations.
The most defensible value proposition is not a novel excipient claim alone. It is a reproducible formulation that reduces development time, passes dissolution and bioequivalence testing, and operates at low cost with stable supply.
Key Takeaways
- The 40/5/25 mg product is a mature, immediate-release fixed-dose antihypertensive combination.
- The core formulation challenge is balancing olmesartan medoxomil dissolution, amlodipine content uniformity, and hydrochlorothiazide manufacturability.
- Direct compression is the preferred commercial starting point when flow and compressibility are adequate.
- Dry granulation is a practical fallback for segregation and flow problems.
- Moisture, light, peroxide, aldehyde, lubrication, and particle-size controls are central to stability and dissolution.
- The product is subject to generic rather than biosimilar competition.
- Commercial opportunity is strongest in generic supply, excipient platforms, smaller tablets, and multi-strength product families.
- Patent risk remains dependent on current Orange Book listings, formulation claims, process claims, and Paragraph IV activity.
FAQs
Can the 40/5/25 mg combination be formulated without lactose?
Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipients can replace lactose, subject to dissolution, stability, compressibility, and bioequivalence evaluation.
Is a bilayer tablet necessary for this three-drug combination?
No. A conventional single-layer tablet is technically feasible. A bilayer design may be considered only if segregation, compatibility, or dissolution problems cannot be controlled in a single blend.
Is sodium stearyl fumarate preferable to magnesium stearate?
It can be useful where magnesium stearate causes excessive hydrophobicity or dissolution slowing. The choice must be supported by tablet strength, disintegration, dissolution, and stability data.
Can the product be developed as an orally disintegrating tablet?
Possibly, but the relatively high total active load and the 25 mg hydrochlorothiazide dose make tablet size, taste, mouthfeel, and mechanical strength difficult. An orally disintegrating format would require a distinct product-development and regulatory strategy.
Do excipient changes create a new patent position?
Usually not by themselves. A patent position would require claims directed to a novel and non-obvious composition, process, stability profile, or performance characteristic. Routine substitution of diluents, binders, or lubricants generally does not create meaningful exclusivity.
References
-
U.S. Food and Drug Administration. (2010). Tribenzor (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) prescribing information. Daiichi Sankyo, Inc.
-
U.S. Food and Drug Administration. (2024). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
United States Patent and Trademark Office. (2024). Patent Center and Patent Public Search. USPTO.
-
U.S. Code. (2024). 21 U.S.C. § 355: New drugs and abbreviated applications; 35 U.S.C. § 271(e): Infringement of patents. United States Code.
